Myers R, Wickerhauser M, Charamella L, Simon L, Nummy W, Brodniewicz-Proba T
Blood Derivatives Section, Michigan Department of Public Health, Lansing.
Vox Sang. 1991;60(3):141-7. doi: 10.1111/j.1423-0410.1991.tb00889.x.
Large-scale adaptation of a recently reported glycine precipitation method for the production of factor VIII (FVIII) concentrate is described. Scaling up of the method required some modification including the addition of aluminum hydroxide to the glycine buffer to reduce the level of contaminating proteins in the final preparation and the use of centrifugation to replace filtration by glass beads. Furthermore, the resultant product was virus inactivated by incorporation of the organic solvent and detergent technique. At industrial level, the modified method gave a good recovery of FVIII activity (230 IU/l plasma) with high purity (4 IU/mg protein). The final product, after virus inactivation and lyophilization, yielded 185 IU of FVIII activity per liter of starting plasma and was considered to be suitable for clinical evaluation.
本文描述了一种最近报道的用于生产凝血因子VIII(FVIII)浓缩物的甘氨酸沉淀法的大规模应用。该方法的放大需要一些改进,包括在甘氨酸缓冲液中添加氢氧化铝以降低最终制剂中污染蛋白的水平,以及使用离心法代替玻璃珠过滤。此外,通过引入有机溶剂和去污剂技术对所得产品进行病毒灭活。在工业规模上,改进后的方法FVIII活性回收率良好(每升血浆230国际单位),纯度高(每毫克蛋白4国际单位)。经过病毒灭活和冻干后的最终产品,每升起始血浆产生185国际单位的FVIII活性,被认为适合进行临床评估。